676515-33-6

Usage

Uses

Used in Pharmaceutical Industry:
1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) is used as an intermediate in the production of pharmaceuticals for its potential antitumor and antifungal activities. Its chemical structure allows it to be a promising candidate in the development of new drugs targeting various diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) serves as a key intermediate, enabling the creation of complex organic molecules with potential applications in various industries.
Used in Antitumor Applications:
1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) is being studied for its potential use in the treatment of cancer due to its antitumor properties. It may contribute to the development of novel therapeutic agents for cancer treatment.
Used in Antifungal Applications:
1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) is also being investigated for its antifungal activities, which could lead to its use in the development of new antifungal medications to combat fungal infections.
Used in Neurological Disorder Treatment:
1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) has been explored for its potential in treating neurological disorders such as Alzheimer's disease, indicating its possible role in the development of neuroprotective agents.
Used in Antimicrobial Applications:
1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) has shown promising antimicrobial properties, suggesting its potential use as an antibiotic agent in the fight against bacterial infections. Further research is necessary to fully understand its therapeutic potential in this area.
While the potential applications of 1,8-Naphthyridin-4(1H)-one,2,3-dihydro-(9CI) are diverse and promising, more research is required to fully understand its therapeutic and industrial applications and to optimize its use in various fields.

InChI:InChI=1/C8H8N2O/c11-7-3-5-10-8-6(7)2-1-4-9-8/h1-2,4H,3,5H2,(H,9,10)

Upstream product

• 64942-87-6 7-bromo-2,3-dihydro-1,8-naphthyridin-4-(1H)one 
• 504-29-0 2-aminopyridine 
• 104961-64-0 3-[(pyridin-2-yl)amino]propanoic acid 

Downstream Products

• 676515-34-7 6-bromo-2,3-dihydro-1,8-naphthyridin-4(1H)-one 

Relevant academic research and scientific papers

PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES

Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: (I), (II) These compounds inhibit Coagulation Factor Xlla in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.

Synthesis and β-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3-dihydrothiopyrano[2,3-b]pyridine: Identification of β3-antagonists

Drugs acting on β1- and β2-adrenergic receptors are widely used for the clinical management of a large number of cardiovascular and respiratory pathologies. In the last decade, the discovery of the third subtype of β receptors, the β3-adrenoceptor, gave a further pharmacological target for the development of new selective drugs. Initially, a potential therapeutic use of β3-selective agents seemed to be restricted to agonists, for the treatment of metabolic diseases, such as obesity, non-insulin-dependent diabetes, urinary frequency and incontinence. More recently, some interesting theories about a negative role played by the cardio-depressant activity of myocardial β 3-adrenoceptors in heart failure, seemed to justify a clinical use of β3-antagonists in the last phases of this cardiac disease. Following the indications deriving from previous experimental work, the β-antagonist properties of newly-synthesised (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and of 2,3-dihydrothiopyrano[2,3-b]pyridine were evaluated, in order to identify some useful structure-activity relationships, which might account for selectivity towards the three β-subtypes and, in particular, the β3-adrenoceptor. Among the various observations regarding possible structure-activity relationships, able to explain the pharmacodynamic patterns of the synthesised compounds on the three subtypes of β-adrenoceptors, the most significant data derived from the evaluation of the β3-blocking properties of some oximeethers of 1,8-naphthyridine derivatives. In these molecules, although the presence of the large substituents in position 7, such as 4-chloro-phenoxy- or 4-t-butyl-phenoxy groups determined a dramatic decline in both the β 1- and β2-activities, this structural characteristic had a modest influence on the β3-affinity, which was only slightly lower. Hence, this last structural requirement of oximeethers of 1,8-naphthyridine derivatives seems to represent a useful expedient to induce an appreciable selectivity towards the β3-receptor, through a markedly negative effect on the β1- and β 2-activities rather than an increase in the β 3-affinity.